Resectable Pancreatic Ductal Adenocarcinoma Clinical Trials

16 clinical trials for Resectable Pancreatic Ductal Adenocarcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE2
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE3
• Targeted Pathway Inhibition in Patients With Pancreatic Cancer — RECRUITING · PHASE1
• Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment — RECRUITING · NA
• Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy — RECRUITING
• Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy — RECRUITING · NA
• SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial — NOT_YET_RECRUITING · PHASE2
• Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer — NOT_YET_RECRUITING · PHASE1
• A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study — WITHDRAWN · PHASE2
• Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma — COMPLETED · PHASE2
• Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer — COMPLETED · PHASE1
• Nalirinox Neo-pancreas RAS Mut ctDNA Study — OTHER · PHASE2
• A Phase II Study of Neoadjuvant FOLFIRINOX — COMPLETED · PHASE2
• The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma — OTHER · PHASE2

Refine this search